Xpovio (selinexor) - 2 indications

Scroll down for more information on each indication:

• for the treatment of adults with multiple myeloma who have received at least one prior therapy in combination with other treatments; approved July 2019 expanded in December 2020 to include relapsed or refractory multiple myeloma in combination
• for adults with relapsed or refractory diffuse large B-cell lymphoma; approved June of 2020

General Information

Xpovio (selinexor) is a nuclear export inhibitor. 

Xpovio is specifically indicated for the following:

• in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
• in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody
• for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Xpovio is supplied as a tablet for oral administration. Scroll down for recommended dosing/administration for each indication.

Mechanism of Action

Xpovio (selinexor) is a nuclear export inhibitor. In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). XPO1 inhibition by selinexor leads to accumulation of TSPs in the nucleus, reductions in several oncoproteins, such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells. Selinexor demonstred pro-apoptotic activity in vitro in multiple myeloma cell lines and patient tumor samples, and in murine xenograft models.

Side Effects

Adverse effects associated with the use of Xopvio in combination with Bortezomib and Dexamethasone (SVd) for the treatment of multiple myeloma may include, but are not limited to, the following:

• fatigue
• nausea
• decreased appetite
• diarrhea
• peripheral neuropathy
• upper respiratory tract infection
• decreased weight
• cataract
• vomiting
• Grade 3-4 laboratory abnormalities including: thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia

Adverse effects associated with the use of Xopvio in combination with dexamethasone (Sd) for the treatment of multiple myeloma may include, but are not limited to, the following:

• thrombocytopenia
• fatigue
• nausea
• anemia
• decreased appetite
• decreased weight
• diarrhea
• vomiting
• hyponatremia
• neutropenia
• leukopenia
• constipation
• dyspnea
• upper respiratory tract infection

Adverse effects associated with the use of Xopvio for the treatment of DLBCL may include, but are not limited to, the following: 

• fatigue
• nausea
• diarrhea
• appetite decrease
• weight decrease
• constipation
• vomiting
• pyrexia
• Grade 3-4 laboratory abnormalities including: thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia

Indication 1 - for the treatment of multiple myeloma

approved July 2019 expanded in December 2020 

Dosing/Administration

In Combination with Bortezomib and Dexamethasone (SVd):

• Recommended dosage of Xpovio is 100 mg taken orally once weekly in combination with bortezomib and dexamethasone

In Combination with Dexamethasone (Sd):

• Recommended dosage of Xpovio is 80 mg taken orally on Days 1 and 3 of each week in combination with dexamethasone

Clinical Trial Results

The FDA approval of Xpovio for adults with relapsed or refractory multiple myeloma was given under accelerated approval status based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 

The accelerated approval was based on results from the Phase 2b STORM (Selinexor Treatment of Refractory Myeloma) trial, which was a multicenter, single-arm, open-label study of patients with RRMM. STORM Part 2 included 122 patients with RRMM. In STORM Part 2, a total of 122 patients were treated with Xpovio (80 mg) in combination with dexamethasone (20 mg) on Days 1 and 3 of every week. Treatment continued until disease progression, death, or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR), as assessed by an Independent Review Committee based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. The approval of Xpovio was based upon the efficacy and safety in a prespecified subgroup analysis of the 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab, as the benefit-risk ratio appeared to be greater in this more heavily pretreated population than in the overall trial population. For the STORM Part 2 study’s major efficacy outcome measure, the ORR was 25.3% in the subgroup of 83 patients, which included one stringent complete response, no complete responses, four very good partial responses and 16 partial responses.  The median time to first response for these patients was 4 weeks and the median duration of response was 3.8 months.

The FDA approval of Xpovio's expanded multiple myeloma indication is supported by the results of the BOSTON study, a multi-center, Phase 3, randomized study, which evaluated 402 adult patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. The study was designed to compare the efficacy, safety and certain health-related quality of life parameters of once-weekly Xpovio in combination with once-weekly Velcade (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade plus dexamethasone (Vd). The primary endpoint of the study was progression-free survival. The median PFS in the SVd arm was 13.9 months compared to 9.5 months in the Vd arm, representing a 4.4 month (47%) increase in median PFS. The SVd arm also demonstrated a significantly greater ORR compared to the Vd arm (76.4% vs. 62.3%).

Indication 2 - for adults with relapsed or refractory diffuse large B-cell lymphoma

approved June of 2020

Dosing/Administration

The recommended dosage of Xpovio is 60 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.

Clinical Trial Results

The FDA approval of Xpovio for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was given under accelerated approval status based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 

The accelerated approval was based on the Phase IIb SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study. The multicenter, single-arm, open-label study enrolled 134 adults with relapsed or refractory DLBCL, not otherwise specified (NOS), after 2 to 5 systemic regimens. Data demonstrated a 29% overall response rate. Of those ORR successes, 13% had a complete response and 16% had partial responses. Key secondary endpoints included a median duration of response (DOR) in the responding patients. In the responding patients, 56% maintained a response at three months, 38% at six months, and 15% at 12 months.